Fatih Akin1, Omer Celik2, Ibrahim Altun3, Burak Ayca4, Vesile Ornek Diker5, Seckin Satılmıs6, Cem Sahin7. 1. Department of Cardiology, Muğla Sıtkı Kocman University School of Medicine, Muğla, Turkey. Electronic address: faith._akin@hotmail.com. 2. Department of Cardiology, Mehmet Akif Ersoy Chest and Cardiovascular Surgery Education and Research Hospital, Istanbul, Turkey. 3. Department of Cardiology, Muğla Sıtkı Kocman University School of Medicine, Muğla, Turkey. 4. Department of Cardiology, Bağcılar Education and Research Hospital, Istanbul, Turkey. 5. Department of Biochemistry, Mehmet Akif Ersoy Chest and Cardiovascular Surgery Education and Research Hospital, Istanbul, Turkey. 6. Department of Cardiology, Acıbadem University, Istanbul, Turkey. 7. Department of Internal Medicine, Muğla Sıtkı Kocman University School of Medicine, Muğla, Turkey.
Abstract
BACKGROUND: Serum fibroblast growth factor 23 (FGF-23) and fetuin-A are established predictors of morbidity and mortality due to cardiovascular disease. The objective of the present study is to evaluate the relationship between coronary artery disease (CAD) and serum concentrations of FGF-23 and fetuin-A. METHODS: A total of 383 subjects who underwent coronary computed tomography angiography (CCTA) were included in the study. CCTA detected CAD in 208 patients; the rest of the patients had no detectable CAD. RESULTS: Serum FGF-23 and fetuin-A levels were significantly increased in CAD patients compared to non-CAD patients (26.6±21.1pg/mL vs. 17.9±16.1pg/mL, p=0.001 and 826±350mg/L vs. 595±300mg/L, p<0.001, respectively). Serum FGF-23, fetuin-A, low-density lipoprotein (LDL)-cholesterol, and uric acid values were elevated in non-diabetic patients with CAD when compared to those without CAD. FGF-23, and fetuin-A were not significantly different in diabetic patients with CAD when compared to those without CAD. Using multivariate logistic regression analysis, we found that age, hypertension, LDL-Cholesterol, high-density lipoprotein (HDL)-Cholesterol, hs-CRP, uric acid, FGF-23 and fetuin-A levels were independently associated with the presence of CAD. CONCLUSION: FGF-23 and fetuin-A were positively correlated with coronary atherosclerosis Similar trends were seen among diabetic patients, but this did not reach statistical significance. FGF-23 and fetuin-A could be used as novel risk markers of cardiovascular disease.
BACKGROUND: Serum fibroblast growth factor 23 (FGF-23) and fetuin-A are established predictors of morbidity and mortality due to cardiovascular disease. The objective of the present study is to evaluate the relationship between coronary artery disease (CAD) and serum concentrations of FGF-23 and fetuin-A. METHODS: A total of 383 subjects who underwent coronary computed tomography angiography (CCTA) were included in the study. CCTA detected CAD in 208 patients; the rest of the patients had no detectable CAD. RESULTS: Serum FGF-23 and fetuin-A levels were significantly increased in CAD patients compared to non-CAD patients (26.6±21.1pg/mL vs. 17.9±16.1pg/mL, p=0.001 and 826±350mg/L vs. 595±300mg/L, p<0.001, respectively). Serum FGF-23, fetuin-A, low-density lipoprotein (LDL)-cholesterol, and uric acid values were elevated in non-diabeticpatients with CAD when compared to those without CAD. FGF-23, and fetuin-A were not significantly different in diabeticpatients with CAD when compared to those without CAD. Using multivariate logistic regression analysis, we found that age, hypertension, LDL-Cholesterol, high-density lipoprotein (HDL)-Cholesterol, hs-CRP, uric acid, FGF-23 and fetuin-A levels were independently associated with the presence of CAD. CONCLUSION:FGF-23 and fetuin-A were positively correlated with coronary atherosclerosis Similar trends were seen among diabeticpatients, but this did not reach statistical significance. FGF-23 and fetuin-A could be used as novel risk markers of cardiovascular disease.
Authors: Anna E Bortnick; Shuo Xu; Ryung S Kim; Bryan Kestenbaum; Joachim H Ix; Nancy S Jenny; Ian H de Boer; Erin D Michos; George Thanassoulis; David S Siscovick; Matthew J Budoff; Jorge R Kizer Journal: Atherosclerosis Date: 2019-04-13 Impact factor: 5.162
Authors: F Roshanzamir; M Miraghajani; M H Rouhani; M Mansourian; R Ghiasvand; S M Safavi Journal: J Endocrinol Invest Date: 2017-06-22 Impact factor: 4.256
Authors: Elżbieta Reichert; Jerzy Mosiewicz; Wojciech Myśliński; Andrzej Jaroszyński; Agata Stanek; Klaudia Brożyna-Tkaczyk; Barbara Madejska-Mosiewicz Journal: Int J Environ Res Public Health Date: 2022-05-25 Impact factor: 4.614
Authors: Martin H Sørensen; Annemie S Bojer; Niklas R Jørgensen; David A Broadbent; Sven Plein; Per L Madsen; Peter Gæde Journal: Cardiovasc Diabetol Date: 2020-09-30 Impact factor: 9.951